MicroTech Medical Forecasts Strong 2025 Growth and Returns to Profit

MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) has issued an update.

MicroTech Medical has issued a positive profit alert for 2025, projecting revenue of at least RMB650 million, up about 88 percent year on year, and a turnaround to a net profit of no less than RMB38 million from a loss in 2024. The improvement is driven by strong growth in its continuous glucose monitoring systems, successful launches of the LinX CGMS in multiple overseas markets, and tighter cost management that has significantly improved operating efficiency, signaling a strengthened competitive position and better prospects for shareholders and investors.

The company emphasized that these figures are based on preliminary unaudited management accounts prepared under PRC accounting standards and may be subject to adjustment. It plans to publish its full 2025 results by the end of March 2026 and has urged shareholders and potential investors to exercise caution when dealing in its shares until the final numbers are released.

The most recent analyst rating on (HK:2235) stock is a Sell with a HK$7.00 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.

More about MicroTech Medical (Hangzhou) Co., Ltd. Class H

MicroTech Medical (Hangzhou) Co., Ltd. is a PRC-based medical technology company focused on diabetes management solutions. Its core products include continuous glucose monitoring systems, such as the LinX CGMS, with a growing emphasis on overseas markets where it has been actively expanding its international presence and distribution.

Average Trading Volume: 138,269

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.07B

Find detailed analytics on 2235 stock on TipRanks’ Stock Analysis page.